IRRAS AB (publ) (IRRAS.ST)
IRRAS AB (publ) operates in the Medical - Devices industry of the Healthcare sector, headquartered in Stockholm, SE. The stock last traded at $0.16, down 1.11% on the session, giving a market capitalisation of $181.7M. Its beta of 1.73 implies it has historically moved more than the broad market.
IRRAS AB (publ), a medical technology company established in 2011 and headquartered in Stockholm, Sweden, is dedicated to developing medical solutions that enhance the lives of critically ill patients globally. The firm specializes in neurocritical care products, aiming to transform patient outcomes and address complexities inherent in current treatment methods. Among its offerings is IRRAflow, an advanced irrigating intracranial drainage system that integrates controlled drainage, automated irrigation, and continuous intracranial pressure (ICP) monitoring, used effectively for treating hemorrhagic strokes and chronic subdural hematoma. Additionally, IRRAS provides the Hummingbird ICP monitoring system, comprising the HICP200 Control Module and various catheters like the H610 for quad ICP monitoring with drainage and the H110 for solo ICP monitoring. These Hummingbird neuromonitoring tools are vital for managing patients with elevated ICP caused by conditions such as traumatic brain injury, subarachnoid hemorrhage, and strokes. The company distributes its products to hospitals through both its direct sales force and a network of strategic distribution partners.
IRRAS AB (publ) is most often compared with the following Healthcare names: